Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
AstraZeneca welcomes new arrivals as Alderley Park BioHub expands
-
Marketing Authorisation Application for naloxegol accepted by European Medicines Agency
-
Marketing Authorisation Application for olaparib accepted by European Medicines Agency
-
New hypoglycemia and pancreatitis subanalyses from the Onglyza® (saxagliptin) SAVOR cardiovascular outcomes trial presented at the 49th annual meeting of the European Association for the Study of Diabetes (EASD)
-
New Phase III data showed dapagliflozin significantly reduced HBA1C compared to placebo at 24 weeks in patients with type 2 diabetes inadequately controlled with the combination of metformin plus sulfonylurea
-
Fluenz Tetra, four-strain nasal spray vaccine, receives positive opinion in EU from CHMP for the prevention of seasonal influenza in children
-
FDA accepts new drug application for investigational compound Epanova for the treatment of severe hypertriglyceridaemia
-
US appeals court issues temporary injunction against Hanmi’s 505(b)2 NDA Esomeprazole Strontium
-
AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer
-
AstraZeneca initiates Phase III clinical programme for olaparib, a treatment in development for patients with BRCA mutated ovarian cancer
Latest articles and press releases
All of our latest press releases and articles are available to explore
